FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 356:2622-2629 June 21, 2007 Number 25 Next

	Since this article has no abstract, we have provided an extract of the first 100 words of the full text and any section headings.

	Full Text PDF PDA Full Text PowerPoint Slide Set Animation Purchase this article Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear

This Journal feature begins with a case vignette that includes a therapeutic recommendation. A discussion of the clinical problem and the mechanism of benefit of this form of therapy follows. Major clinical studies, the clinical use of this therapy, and potential adverse effects are reviewed. Relevant formal guidelines, if they exist, are presented. The article ends with the author's clinical recommendations.

A 30-year-old woman was evaluated for consideration of treatment options for multiple sclerosis. Two years earlier she had reported having vertigo. The diagnosis of multiple sclerosis was confirmed by clinical evaluation, examination of cerebrospinal fluid, and magnetic resonance imaging . . . [Full Text of this Article]

The Clinical Problem

Pathophysiology and Effect of Therapy

Clinical Evidence

Clinical Use

Adverse Effects

Areas of Uncertainty

Guidelines

Recommendations

Source Information

From the Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, Cleveland.

Address reprint requests to Dr. Ransohoff at the Neuroinflammation Research Center, Department of Neurosciences, Lerner Research Institute and Mellen Center for Multiple Sclerosis Treatment and Research, Neurological Institute, Cleveland Clinic, NC30, 9500 Euclid Ave., Cleveland, OH 44195, or at ransohr@ccf.org.

This article has been cited by other articles:

• Chen, Y., Bord, E., Tompkins, T., Miller, J., Tan, C. S., Kinkel, R. P., Stein, M. C., Viscidi, R. P., Ngo, L. H., Koralnik, I. J. (2009). Asymptomatic Reactivation of JC Virus in Patients Treated with Natalizumab. NEJM 361: 1067-1074 [Abstract] [Full Text]  
• Bauer, M., Brakebusch, C., Coisne, C., Sixt, M., Wekerle, H., Engelhardt, B., Fassler, R. (2009). {beta}1 integrins differentially control extravasation of inflammatory cell subsets into the CNS during autoimmunity. Proc. Natl. Acad. Sci. USA 106: 1920-1925 [Abstract] [Full Text]  
• Khatri, B. O., Man, S., Giovannoni, G., Koo, A. P., Lee, J-C, Tucky, B., Lynn, F., Jurgensen, S., Woodworth, J., Goelz, S., Duda, P. W., Panzara, M. A., Ransohoff, R. M., Fox, R. J. (2009). Effect of plasma exchange in accelerating natalizumab clearance and restoring leukocyte function. Neurology 72: 402-409 [Abstract] [Full Text]  
• Wekerle, H (2008). Lessons from multiple sclerosis: models, concepts, observations. Ann Rheum Dis 67: iii56-iii60 [Abstract] [Full Text]  
• Rossi, D., Zucchetto, A., Rossi, F. M., Capello, D., Cerri, M., Deambrogi, C., Cresta, S., Rasi, S., De Paoli, L., Bodoni, C. L., Bulian, P., Del Poeta, G., Ladetto, M., Gattei, V., Gaidano, G. (2008). CD49d expression is an independent risk factor of progressive disease in early stage chronic lymphocytic leukemia. haematol 93: 1575-1579 [Abstract] [Full Text]  
• Linker, R. A., Kieseier, B. C. (2008). Review: Innovative monoclonal antibody therapies in multiple sclerosis. Therapeutic Advances in Neurological Disorders 1: 33-42 [Abstract]  
• Nowakowski, G. S. (2008). Gang of 3 in aggressive CLL?. Blood 112: 5-6 [Full Text]  
• Metzler, B., Haubner, B., Conci, E., Voelkl, J., Jehle, J., Bauer, M., Wolf, D., Pachinger, O., Xu, Q. (2008). Myocardial ischaemia-reperfusion injury in haematopoietic cell-restricted {beta}1 integrin knockout mice. Exp Physiol 93: 825-833 [Abstract] [Full Text]  
• Jalkanen, S., Salmi, M. (2008). VAP-1 and CD73, Endothelial Cell Surface Enzymes in Leukocyte Extravasation. Arterioscler. Thromb. Vasc. Bio. 28: 18-26 [Abstract] [Full Text]